MEA Adoption Challenges in Advanced Therapy Med...

By João L. Carapinha

May 11, 2026

MEA Adoption Challenges continue to limit the practical use of Managed Entry Agreements for Advanced Therapy Medicinal Products across Europe. The 2026 pre-proof paper by Greco et al. draws on interviews with HTA bodies and payers in England, the ...
Dutch Elderly Care Challenges: Navigating Fragmentation in Support Systems
Compliance Challenges Under the New Procurement Regulations South Africa for ...
Preferential Procurement Regulations: Impact on Health Sector Suppliers in 2026
Strategic Procurement Regulations: Navigating South Africa’s 2026 Frame...
FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases
EUCOPE Pharmaceutical Regulation: Advocating for Innovative SMEs in a Changin...
Unlocking the Benefits of Cardiovascular Health Checks in EU Prevention Strat...
Rui Santos Ivo Advocates for Regulatory Frameworks Innovation at RAPS Euro Co...
MFN Drug Pricing Savings: Projected $593 Billion in U.S. Healthcare Savings O...
Sandoz Mobile Health Initiative: Empowering Communities Through Accessible Care
Strategic Investment Boosts Medical Device Distribution in Africa
Navigating the Challenges of Patient-Centered AI Systems in Postpartum Depres...